DrugPatentWatch Database Preview

Galderma Labs Lp Company Profile

GALDERMA LABS LP has twenty-three approved drugs.

There are sixty-one US patents protecting GALDERMA LABS LP drugs.

There are three hundred and forty patent family members on GALDERMA LABS LP drugs in thirty-three countries and ninety-eight supplementary protection certificates in fifteen countries.

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	TRI-LUMA	fluocinolone acetonide; hydroquinone; tretinoin	CREAM;TOPICAL	021112-001	Jan 18, 2002		RX	Yes	Yes	8,247,395	➤ Sign Up	Y			➤ Sign Up
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013		RX	Yes	Yes	7,439,241	➤ Sign Up				➤ Sign Up
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006		RX	Yes	Yes	8,470,364	➤ Sign Up	Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	5,952,372	➤ Sign Up
Galderma Labs Lp	CLOBEX	clobetasol propionate	SPRAY;TOPICAL	021835-001	Oct 27, 2005	5,990,100	➤ Sign Up
Galderma Labs Lp	ORACEA	doxycycline	CAPSULE;ORAL	050805-001	May 26, 2006	5,789,395	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Topical Gel	0.30%	➤ Subscribe	2009-09-15
➤ Subscribe	Gel	0.1%/2.5%	➤ Subscribe	2011-12-30
➤ Subscribe	Topical Gel	0.33%	➤ Subscribe	2014-12-15
➤ Subscribe	Spray	0.05%	➤ Subscribe	2008-09-29
➤ Subscribe	Delayed-release Capsules	40 mg	➤ Subscribe	2008-12-11
➤ Subscribe	Cream	1%	➤ Subscribe	2016-12-30
➤ Subscribe	Topical Gel	1%	➤ Subscribe	2008-10-21
➤ Subscribe	Lotion	0.05%	➤ Subscribe	2006-03-27
➤ Subscribe	Topical Shampoo	0.05%	➤ Subscribe	2008-01-09

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2014	Austria	➤ Sign Up	PRODUCT NAME: (1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXOLAN-3-YL)OXY(PHENYL)METHYL)PHENYL)-D-GLUCITOL (EMPAGLIFLOZIN); REGISTRATION NO/DATE: EU/1/14/930 (MITTEILUNG) 20140527
11/039	Ireland	➤ Sign Up	PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-Y1)-7-BUT-2INYL-3-METHYL-1-(4- METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2,6-DION THE ENATIOMERS AND SALTS THEROF-ESPECIALLY LINAGLIPTIN."LINAGLIPTIN=((R)-8-(3-AMINOPIPERIDIN-1-YL)- 7-BUT-2-INYL-3-METHYL-L-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6- DION") (IUPAC); REGISTRATION NO/DATE: EU/1/11/707/001-EU/1/11/707/011 20110824
90049-2	Sweden	➤ Sign Up	PRODUCT NAME: BRIMONIDIN OCH FARMACEUTISKA SALTER DAERAV; REG. NO/DATE: EU/1/13/904 20140221
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.